



7-15-05

DPW

CASE 4-31321B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV7224872524S
Express Mail Label Number

July 14, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BOLD ET AL. 10/766,181

APPLICATION NO: 10/776,184

FILED: JANUARY 27, 2004

FOR: PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR
VEGF RECEPTOR TYROSINE KINASE

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Applicants hereby respond to the Official Action mailed June 16, 2005, in the above identified application. Reconsideration and allowance of all the pending claims is respectfully requested.

Election/Restriction Requirement

The Official Action has required the applicants to elect a single invention and designate a single species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held allowable.

Applicants hereby elect with traverse, Group I, Claims 1-18 and 21.

The Official Action has also required the applicants to designate a single species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held allowable.

Applicants hereby designate the species with the following definitions:

B and E are each CH;

A or D is N while the other is CH;

T is CR₄

R₄ is Cl, free, etherified or esterified hydroxy preferably OH or OMe, for this species

election R₄ is OMe;

G is C₁ alkylene;

and W is Me.


The species elected is represented by the Examples 47-48 and the compound on page 72 of the specification.

In addition, in response to the requirement to designate claims readable on the designated species, applicants further submit that claims 1-6, 9, and 17-21 are readable on the designated species.

The above designations are made with the understanding that this application is not limited to the designated species, and with the understanding that upon allowance of a claim generic to the designated species, applicants will be entitled to examination in this application of additional species.

Entry of this response is respectfully requested.

Respectfully submitted,



Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898

Date: July 14, 2005